ORLANDO, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO, Gareth Sheridan will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Thursday, June 5th at 4PM Eastern Standard Time. The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience. Scheduled 1x1 meetings with the Company are also available for registered, qualified investor attendees. Attendees interest ...

ORLANDO, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the first quarter ended April 30, 2025. Nutriband is continuing to expand its kinesiology tape output through its Pocono Pharma subsidiary, with a continued focus on penetration pricing to gain a foothold with some of the industry’s largest brands. The Company produced a record first quarter reporting revenue of $667,000USD, up 63% % YOY. Pocono manufactured products continue to ro ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 000-55654 NUTRIBAND INC. (Exact name of registrant as specified in its charter) | NEVADA | 81-1118176 | | --- | --- | | (State ...

ORLANDO, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2024 and the potential outlook for 2025. The full text of the letter is below. Dear Shareholders, Following the filing of our annual report as we wrap up a successful year packed with milestones and advances towards the commercialization of our AVERSA technology, the entire team ...

Financial Performance - For the year ending January 31, 2025, the company generated revenue of $2,139,537, a 2.6% increase from $2,085,314 in the previous year[165]. - The company's gross margin for the year ending January 31, 2025, was $743,317, down from $862,105 in the prior year, primarily due to lower margins on tape sales[165]. - The company incurred a net loss of $10,482,617, or $(0.99) per share, for the year ended January 31, 2025, compared to a loss of $5,485,314, or $(0.69) per share, for the previous year[171]. - Selling, general and administrative expenses increased to $4,313,810 for the year ending January 31, 2025, from $3,773,606 in the previous year, primarily due to higher non-cash compensation and public relations costs[166]. - The company has not generated any revenue from its 4P Therapeutics segment for the year ending January 31, 2025, due to a shift in focus and the winding down of the main contract[165]. - The company anticipates an increase in demand for its products in the subsequent year, despite the decline in gross margin[165]. Research and Development - Research and development expenses for the Aversa Fentanyl product amounted to $3,119,134 for the year ending January 31, 2025, compared to $1,960,425 in the previous year, reflecting increased labor and material costs[167]. - Research and development costs are expensed as incurred, indicating a focus on innovation and product development[201]. Cash and Working Capital - As of January 31, 2025, the company had cash and cash equivalents of $4,311,719 and working capital of $3,811,420, significantly up from $492,942 and $22,770, respectively, as of January 31, 2024[172]. - As of January 31, 2025, the Company had cash and cash equivalents totaling $3,804,000, exceeding federally insured cash balance limits[189]. Impairment and Goodwill - An impairment charge of $3,595,216 was recorded during the year ending January 31, 2025, reducing the value of goodwill and intangible assets[168]. - Goodwill amounted to $1,719,535 as of January 31, 2025, down from $5,021,713 as of January 31, 2024, following an impairment charge of $3,302,478 during the year[194]. - The Company recorded an impairment charge of $293,038 to its intellectual property during the year ending January 31, 2025[193]. Inventory and Accounts Receivable - As of January 31, 2025, the total inventory was $212,041, consisting of work-in-process of $46,255, finished goods of $16,609, and raw materials of $149,177, compared to $168,605 in total inventory as of January 31, 2024[191]. - The Company recorded bad debt expenses of $1,200 and $11,836 for doubtful accounts related to accounts receivable for the years ended January 31, 2025, and 2024, respectively[190]. - The Company maintains allowances for doubtful accounts based on specific identification and historical loss application, reflecting a proactive approach to credit risk management[190]. Accounting Policies - The Company completed necessary changes to its accounting policies and internal controls to comply with lease accounting standards[200]. - The Company recognizes deferred tax assets and liabilities based on the differences between financial statements and tax basis, using enacted tax rates[203]. - The Company applies a straight-line depreciation method for property, plant, and equipment, with useful lives ranging from 3 to 20 years[192].

ORLANDO, Fla., April 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received notification that its patent has been granted in Macao for its patent entitled, "Abuse and Misuse Deterrent Transdermal Systems," which protects its AVERSA™ abuse deterrent transdermal technology. The Macao Intellectual Property Office granted patent J/9010 on February 11, 2025 as recorded ...

Core Insights - Nutriband Inc. has signed an Associate Partnership agreement with Charlotte FC to enhance brand visibility, particularly for its AI Tape product manufactured locally in Charlotte [1][2] - The partnership aims to promote Nutriband's AVERSA technology, which is positioned as a potential breakthrough in abuse deterrent patches for chronic pain management [3][4] Company Overview - Nutriband Inc. focuses on developing transdermal pharmaceutical products, with its lead product being an abuse deterrent fentanyl patch utilizing AVERSA technology [4] - AVERSA technology is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, and can be integrated into any transdermal patch [4]

Core Insights - Nutriband Inc. has signed an Associate Partnership agreement with Charlotte FC to enhance brand visibility, particularly for its AI Tape product manufactured locally in Charlotte [1][2] - The partnership aims to promote Nutriband's AVERSA platform technology, which is positioned as a potential first-of-its-kind abuse deterrent patch for chronic pain management [3] - Nutriband is focused on developing a portfolio of transdermal pharmaceutical products, with its lead product being an abuse deterrent fentanyl patch utilizing AVERSA technology [4] Company Overview - Nutriband Inc. specializes in transdermal pharmaceutical products, with a manufacturing facility located in North Carolina [2][4] - The AVERSA technology is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, and can be integrated into any transdermal patch [4]

Core Points - Nutriband Inc. has received trademark registration for "Nutriband™" from the USPTO, which is crucial for the commercialization of its AVERSA technology [1][2] - The AVERSA technology aims to prevent the abuse and misuse of drugs, with the lead product being AVERSA™ Fentanyl, a transdermal system designed to deter abuse [2][6] - Nutriband is collaborating with Kindeva Drug Delivery to scale up the commercial manufacturing process for AVERSA™ Fentanyl, which is intended for FDA approval [3] - A market analysis indicates that AVERSA™ Fentanyl could achieve peak annual U.S. sales between $80 million and $200 million, highlighting the potential market impact of the technology [4] - The AVERSA™ technology incorporates aversive agents into transdermal patches to deter drug abuse, particularly for high-abuse-potential medications like fentanyl [5] - Nutriband is focused on developing a range of transdermal pharmaceutical products, with a strong intellectual property portfolio supporting its AVERSA technology [6]

Core Insights - Nutriband has formalized an exclusive product development partnership with Kindeva Drug Delivery to develop Aversa™ Fentanyl, which integrates Nutriband's abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch [1][2] - The partnership involves shared development costs in exchange for milestone payments, indicating a long-term commitment between the two companies [2] Company Overview - Nutriband is focused on developing prescription transdermal pharmaceutical products, with Aversa™ Fentanyl being its lead product under development [5] - The Aversa™ technology aims to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, particularly opioids and stimulants [2][4] Technology Details - Aversa™ abuse-deterrent technology employs a proprietary aversive agent coating that utilizes taste aversion to deter oral abuse and accidental exposure to transdermal opioid and stimulant patches [3] - The technology is protected by a broad international intellectual property portfolio, with patents issued in 46 countries, including the United States, Europe, Japan, and China [3][4] Market Potential - Aversa™ Fentanyl has the potential to be the world's first abuse-deterrent opioid patch, with projected peak annual U.S. sales estimated between $80 million and $200 million [4]